Variable | OS | PFS | LRFS | DMFS | ||||
---|---|---|---|---|---|---|---|---|
HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
Age (≥ 59 vs. < 59 years) | 1.387 (0.517–3.723) | 0.516 | 0.532 (0.264–1.071) | 0.077 | 0.789 (0.322–1.932) | 0.604 | 0.619 (0.296–1.292) | 0.201 |
Sex (male vs. female) | 0.694 (0.197–2.443) | 0.570 | 1.234 (0.603–2.527) | 0.565 | 0.898 (0.324–2.492) | 0.837 | 1.286 (0.605–2.735) | 0.513 |
Stage of primary tumor (I vs. II vs. III) | 1.308 (0.700–2.447) | 0.400 | 1.173 (0.775–1.775) | 0.451 | 1.084 (0.643–1.827) | 0.762 | 1.189 (0.758–1.863) | 0.451 |
Histology (squamous cell carcinoma vs. non-squamous cell carcinoma) | 0.755 (0.261–2.183) | 0.604 | 1.125 (0.510–2.482) | 0.770 | 0.750 (0.270–2.085) | 0.582 | 1.420 (0.582–3.466) | 0.441 |
Recurrence site (stump vs. regional lymph nodes vs. ipsilateral lung vs. multiple sites) | 1.292 (0.689–2.423) | 0.425 | 1.284 (0.767–2.149) | 0.342 | 1.439 (0.780–2.655) | 0.245 | 1.433 (0.840–2.445) | 0.187 |
Interval between surgery and recurrence (≥ 10 vs. < 10 months) | 0.882 (0.328–2.373) | 0.803 | 0.690 (0.352–1.351) | 0.279 | 1.054 (0.434–2.559) | 0.908 | 0.655 (0.320–1.339) | 0.246 |
BED of radiation (≥ 78 vs. < 78 Gy) | 0.347 (0.119–1.013) | 0.053 | 0.905 (0.466–1.758) | 0.769 | 0.288 (0.104–0.795) | 0.016 | 1.075 (0.531–2.175) | 0.841 |
Concurrent chemotherapy (yes vs. no) | 1.222 (0.348–4.294) | 0.754 | 1.114 (0.485–2.555) | 0.799 | 1.247 (0.412–3.774) | 0.696 | 1.150 (0.471–2.808) | 0.758 |
EGFR status (wild-type vs. mutation type vs. unknown) | 0.265 (0.063–1.112) | 0.069 | 0.509 (0.238–1.088) | 0.509 | 1.694 (0.465–6.175) | 0.425 | 0.418 (0.192–0.912) | 0.028 |
Radiation technique (3D-CRT vs. IMRT vs. SBRT) | 2.562 (0.887–7.395) | 0.082 | 1.213 (0.554–2.654) | 0.630 | 2.047 (0.757–5.537) | 0.158 | 1.130 (0.472–2.701) | 0.784 |
GTV (≥ 28.7 vs. < 28.7 cm3) | 1.864 (0.637–5.455) | 0.256 | 1.246 (0.593–2.617) | 0.561 | 0.543 (0.201–1.470) | 0.230 | 1.525 (0.682–3.411) | 0.304 |